CN104203244A - 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物 - Google Patents

包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物 Download PDF

Info

Publication number
CN104203244A
CN104203244A CN201380012366.4A CN201380012366A CN104203244A CN 104203244 A CN104203244 A CN 104203244A CN 201380012366 A CN201380012366 A CN 201380012366A CN 104203244 A CN104203244 A CN 104203244A
Authority
CN
China
Prior art keywords
pharmaceutical
nevirapine
antiretroviral
composition according
lamivudine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380012366.4A
Other languages
English (en)
Chinese (zh)
Inventor
吉纳·马尔霍特拉
什里尼瓦斯·马杜卡尔·普兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN104203244A publication Critical patent/CN104203244A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380012366.4A 2012-03-05 2013-03-05 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物 Pending CN104203244A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN583MU2012 2012-03-05
IN583/MUM/2012 2012-03-05
PCT/GB2013/000092 WO2013132208A1 (en) 2012-03-05 2013-03-05 Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine

Publications (1)

Publication Number Publication Date
CN104203244A true CN104203244A (zh) 2014-12-10

Family

ID=47884388

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380012366.4A Pending CN104203244A (zh) 2012-03-05 2013-03-05 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物

Country Status (13)

Country Link
US (1) US20150104511A1 (enExample)
EP (1) EP2822560A1 (enExample)
JP (1) JP2015509524A (enExample)
KR (1) KR20140138837A (enExample)
CN (1) CN104203244A (enExample)
AU (1) AU2013229274A1 (enExample)
BR (1) BR112014021927A2 (enExample)
CA (1) CA2866133A1 (enExample)
IN (1) IN2014MN01907A (enExample)
MX (1) MX2014010337A (enExample)
RU (1) RU2014140177A (enExample)
WO (1) WO2013132208A1 (enExample)
ZA (1) ZA201406495B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124092A2 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
CA3103522C (en) * 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
EP4172157B1 (en) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026156A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513917T4 (da) 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
GB9622681D0 (en) 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
PT1054867E (pt) 1998-01-16 2004-09-30 Medivir Ab Antivirais
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EP1610797A1 (en) 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of nevirapine and a further antiretroviral compound
WO2008154234A2 (en) * 2007-06-08 2008-12-18 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026156A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKAO NITANDA,ET AL.: "Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine In Vitro", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》, vol. 49, no. 8, 31 August 2005 (2005-08-31), pages 3355 - 3360, XP055062484, DOI: doi:10.1128/AAC.49.8.3355-3360.2005 *

Also Published As

Publication number Publication date
JP2015509524A (ja) 2015-03-30
EP2822560A1 (en) 2015-01-14
ZA201406495B (en) 2016-03-30
CA2866133A1 (en) 2013-09-12
IN2014MN01907A (enExample) 2015-07-10
KR20140138837A (ko) 2014-12-04
BR112014021927A2 (pt) 2019-09-24
US20150104511A1 (en) 2015-04-16
MX2014010337A (es) 2014-11-14
AU2013229274A1 (en) 2014-09-04
WO2013132208A1 (en) 2013-09-12
RU2014140177A (ru) 2016-04-27
WO2013132208A8 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
CN104203244A (zh) 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物
AU2013336491B2 (en) Pharmaceutical antiretroviral composition
WO2014184553A1 (en) Pharmaceutical antiretroviral compositions
UA110853C2 (uk) Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
TWI494133B (zh) 重組用粉末
MXPA06006586A (es) Metodos de dosificacion para la terapia antiviral con beta-d-2',3'-didesoxi-2',3'-dideshidro-5-fluorocitidina.
WO2013057469A1 (en) Pharmaceutical antiretroviral compositions
CA2835272A1 (en) Pharmaceutical antiretroviral composition
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
CA2584670A1 (en) Combination therapy for treating viral infections
TW201542212A (zh) 包括恩曲他濱、泰諾福韋、地瑞那韋與利托那韋的單位劑量形式以及包括地瑞那韋與利托那韋的單體錠劑
WO2009037449A1 (en) Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
EP2844231A1 (en) Antiretroviral composition
WO2018028841A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017029226A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141210

WD01 Invention patent application deemed withdrawn after publication